From: Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Identifier No. | Interventions | Setting | Primary outcome |
---|---|---|---|
NCT03859128 (JUPITER 04) | Toripalimab or placebo | Phase 2, 3 | RFS |
NCT03383458 (CheckMate 9DX) | Nivolumab or placebo | Phase 3 | RFS |
NCT03867084 (KEYNOTE-937) | Pembrolizumab | Phase 3, Double-blinded, Placebo controled | RFS, OS |
Camrelizumab plus Apatinib | Â | Â | |
NCT04102098 (IMbrave050) | Atezolizumab plus Bevacizumab | Phase 3, open label, two arms (versus active surveillence) | RFS |
NCT03847428 (EMERALD-2) | Durvalumab plus bevacizumab or durvalumab monotherapy or placebo | Phase 3, randomized, double-blind, placebo-controlled | RFS |
NCT04418401 (CISLD-8) | Donafenib plus any anti-PD-1 antibody | Phase 1 | 1-year RFS |
Nivolumab and Ropeginterferon alfa-2b | Phase I/II Open Label | RFS |